The U.S. FDA’s complete response letter (CRL) for Biohaven Ltd.’s lead asset, troriluzole, to treat spinocerebellar ataxia has prompted a wave of downstream changes at the company. There will be a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback